ARDX - ア―デリックス （Ardelyx Inc.） ア―デリックスARDXのチャート
ARDXの企業情報
| symbol | ARDx |
|---|---|
| 会社名 | Ardelyx Inc （ア―デリックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アーデリックス(Ardelyx Inc.)は臨床段階のバイオ医薬品会社である。同社の治療法は心臓麻痺及び胃腸（GI）疾患の治療に重点を置く。同社はバイオ医薬品の研究、開発と商品化事業を通じて事業を運営する。同社の製品ラインには、心臓血管系ポートフォリオと胃腸ポートフォリオを含む。同社の心臓血管系ポートフォリオは慢性腎疾患（CKD）と心不全患者にある高カリウム血症の治療向け第III相臨床開発中のRDX7675及び透析末期腎疾患（ESRD）患者にある高リン酸血症治療向け第III相臨床開発中のtenapanorという2つの第III相臨床製品候補を含む。心臓血管系ポートフォリオには、tenapanor、RDX7675、RDX013及びRDX011を含む。胃腸ポートフォリオは便秘を伴う過敏性腸症候群（IBS-C）の治療のために、tenapanorによって導かれる。胃腸ポートフォリオには、tenapanor、RDX8940、RDX011及びRDX023が含まれる。 ア―デリックスは米国の臨床段階のバイオ医薬品企業。GIおよび代謝性疾患の治療ための胃腸管で排他的に動作する小分子治療薬の発見、開発、商業化に焦点を当てている。製品候補のTenapanorは、胃腸管におけるナトリウムのトランスポ―タ―の阻害剤投与小分子の経口剤。 Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA is currently under review by the FDA, with a PDUFA date of April 29, 2021. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. In addition, Ardelyx received FDA approval of IBSRELA® (tenapanor) on September 12, 2019. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories. |
| 本社所在地 | 34175 Ardenwood Boulevard Suite 200 Fremont CA 94555 USA |
| 代表者氏名 | David M. Mott デビッド・モット |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 510-745-7047 |
| 設立年月日 | 39356 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 75人 |
| url | www.ardelyx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ardx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -47.36200 |
| 終値（lastsale） | 3.96 |
| 時価総額（marketcap） | 245732853.96 |
| 時価総額 | 時価総額（百万ドル） 248.21500 |
| 売上高 | 売上高（百万ドル） 44.35000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 84.32000 |
| 当期純利益 | 当期純利益（百万ドル） -49.92000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Ardelyx Inc revenues increased from $0K to $2.4M. Net loss decreased 27% to $39.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development - other decrease of 32% to $27.5M (expense) Stock-based Compensation in Research and decrease of 23% to $1.9M (expense). |
ARDXのテクニカル分析
ARDXのニュース
Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis 2021/07/19 20:01:00 Yahoo Finance
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it received a letter from the U.S. Food and Drug Administration (the "FDA") on July 13, 2021, stating that, as part of its ongoing review of the company''s New Drug Application ("NDA") for the control of serum phosphorus in adult patients with chronic
Ardelyx ($ARDX $NASDAQ) Analyst Coverage Initiated | Live Trading News 2021/07/05 15:05:25 Live Trading News
Prices are vulnerable to a correction towards 7.26, BUY THE DIPThe projected upper bound is: 18.66.The projected lower bound is: 7.11..
ArdCoin (ARDX) is now available on UniSwap | NewsBTC 2021/06/22 18:58:39 NEWSBTC
Ulaanbaatar, Mongolia, 2021/06/18 - Mongolias first and only blockchain-based loyalty reward program ArdCoin is turning a new page in its history as it lists
Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021 2021/06/07 12:00:00 PR Newswire
FREMONT, Calif. and WALTHAM, June 7, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced two presentations
42 Biggest Movers From Yesterday 2021/04/16 10:07:11 Benzinga
Gainers Esports Technologies, Inc. (NASDAQ: EBET ) shares jumped 507% to settle at $36.42 on Thursday. agilon health, inc. (NYSE: AGL ) gained 34.8% to close at $31.00 after the company priced its IPO at $23 a share. Wilhelmina International, Inc. (NASDAQ: WHLM ) shares climbed 29.8% to close at $10.80 on Thursday after gaining 14% on Wednesday. The company's 13D filing recently showed that Modell's Sporting Goods had reported a stake of 18.4% in the company. Kaspien Holdings Inc. (NASDAQ: KSPN ) gained 19.4% to close at $26.91 following Q4 results. Karat Packaging Inc. (NASDAQ: KRT ) climbed 16% to close at $18.56 after the company priced its IPO at $16 per share. PLBY Group, Inc. (NASDAQ: PLBY ) jumped 15.8% to close at $42.58. Elite Education Group International Limited (NASDAQ: EEIQ ) shares jumped 14.2% to close at $6.60. Ballantyne Strong, Inc (NYSE: BTN ) gained 13.8% to close at $4.61. Eton Pharmaceuticals, Inc. (NASDAQ: ETON ) rose 13.1% to settle at $8.56. Weingarten Realty Investors (NYSE: WRI ) gained 12.6% to close at $30.77 after the company announced a strategic merger agreement with Kimco Realty.
Analyzing Ardelyx (NASDAQ:ARDX) and Rigel Pharmaceuticals (NASDAQ:RIGL) 2021/03/14 06:01:09 Modern Readers
Ardelyx (NASDAQ:ARDX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations. Analyst Ratings This is a breakdown of recent ratings and target prices for Ardelyx and Rigel […]
Ardelyx (NASDAQ:ARDX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS 2021/03/11 10:12:41 Transcript Daily
Ardelyx (NASDAQ:ARDX) announced its quarterly earnings data on Sunday. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.06), MarketWatch Earnings reports. Ardelyx had a negative net margin of 1,063.74% and a negative return on equity of 53.93%. Shares of ARDX opened at $6.26 on Tuesday. […]
Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights 2021/03/08 13:00:00 PR Newswire
FREMONT, Calif. and WALTHAM, Mass., March 8, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business highlights…
Ardelyx Is it time to Buy before this week’s earning report Stock market Insights & financial analysis 2021/03/04 22:07:00 Stock Market Daily
Ardelyx announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Analyzing Ardelyx (NASDAQ:ARDX) and Rigel Pharmaceuticals (NASDAQ:RIGL) 2021/03/14 06:01:09 Modern Readers
Ardelyx (NASDAQ:ARDX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations. Analyst Ratings This is a breakdown of recent ratings and target prices for Ardelyx and Rigel […]
Ardelyx (NASDAQ:ARDX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS 2021/03/11 10:12:41 Transcript Daily
Ardelyx (NASDAQ:ARDX) announced its quarterly earnings data on Sunday. The biopharmaceutical company reported ($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.06), MarketWatch Earnings reports. Ardelyx had a negative net margin of 1,063.74% and a negative return on equity of 53.93%. Shares of ARDX opened at $6.26 on Tuesday. […]
Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights 2021/03/08 13:00:00 PR Newswire
FREMONT, Calif. and WALTHAM, Mass., March 8, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business highlights…